🆚 SitePad vs. WebSite X5
- 📈 WebSite X5 is much more popular than SitePad.
- 🌎 WebSite X5 is more popular in Italy, Germany, and the United States.
- 🌍 SitePad is more popular in South Africa, India, and Indonesia.
Type
About
SitePad is a drag-and-drop website builder with over 800 professional themes and integrations with 
cPanel, 
Plesk, and Directadmin.
Incomedia WebSite X5 is a website builder software for 
Windows that lets users create websites, blogs, online stores, digital photo albums, and interactive presentations using a visual interface.
It offers drag-and-drop interface, supports unlimited pages, provides over 100 customizable templates, includes built-in tools for image editing and automatic compression, and comes with SEO-optimization and site analytics features.
Headquarters
Pricing
(1 site) $12/year
(3 sites) $24/year
(10 sites) $36/year
Categories
Popularity
Determined by the number of sites using each technology.
Market share
Popularity by country
Determined by the number of sites detected from each country.
Awards
- 🥉 Third most popular in Italy in the Website Builders category.
- ⭐ 6th most popular in Italy in the E-Commerce category.
- ⭐ 8th most popular in Germany in the Website Builders category.
- ⭐ 9th most popular in Switzerland in the Website Builders category.
- ⭐ 10th most popular in Switzerland in the E-Commerce category.
Popularity by domain category
Determined by the number of sites in each category.
Top sites
Top-ranked sites that use these technologies.
Compare alternatives
Technologies with similar characteristics.
GoDaddy Website Builder
Kajabi
BaseKit
Web Presence Builder
Sitejet
Adobe DreamWeaver
Mobirise
Nicepage🗃️ About This Data
- We evaluate the popularity of technologies based on the number of websites where we detect their usage.
- Technologies without a detectable web footprint, and those we do not track, are not reflected in the calculated market share.
- This report is based on the analysis of 3,603,958 websites.
- Statistics were last calculated on .
- For more details, see our methodology and disclaimer.